ProCE Banner Activity

Injectable Long-Acting CAB + RPV: Choices for Mode of Use

Clinical Thought
In this commentary, I share the factors I consider when deciding whether or not to recommend use of the optional 4-week oral lead-in before initiating long-acting cabotegravir plus rilpivirine injections and my thoughts on every-month vs every-2-month dosing.

Released: August 12, 2022

Expiration: August 11, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Darrell H. S. Tan, MD, FRCPC, PhD: researcher: AbbVie, Gilead Sciences, GlaxoSmithKline.